MiR-380 inhibits the proliferation and invasion of cholangiocarcinoma cells by silencing LIS1
Cancer Cell International,
Abstract Background The objective of this study was to determine the role and regulatory mechanism of miR-380 in…
Abstract Background The objective of this study was to determine the role and regulatory mechanism of miR-380 in…
Abstract Objective This study aimed to construct a model based on 23 enrolled molecules to evaluate prognoses of pT2/3N0M0…
Abstract Background Gastric cancer (GC) remains a malignant tumor with high morbidity and mortality, accounting for…
Abstract Background Long non-coding RNAs (lncRNAs) are key regulators of the 6-methyladenosine (m6A) epigenetic modification…
Abstract Background A higher number of tumor buds in the invasive front of colorectal cancer (CRC) specimens has been shown to…
Os Institutos Nacionais de Saúde (NIH) estão financiando pesquisas sobre como aumentar a aceitação da vacina contra o papilomavír…
Abstract Background The role of Acyl-CoA dehydrogenase long chain (ACADL) in different tumor types had different inhibiting or…
Abstract Tongue squamous cell carcinoma (TSCC) is an aggressive oral cancer with a high incidence of metastasis and poor…
COPENHAGEN, Denmark--(BUSINESS WIRE)-- Genmab A/S (Nasdaq: GMAB) andPfizer, Inc.
Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE PFE) today announced that the European Medicines Agency (EMA) has validated…
Company Website: https://www.genmab.com COPENHAGEN, Denmark -- (Business Wire) Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc.
__.
Media Release COPENHAGEN, Denmark; February 2, 2024 Validation is supported by data from Phase 3 innovaTV 301 trial Genmab A/S (N…
Media Release COPENHAGEN, Denmark; February 2, 2024 Validation is supported by data from Phase 3 innovaTV 301 trial (Nasdaq…
Media Release COPENHAGEN, Denmark; February 2, 2024 Validation is supported by data from Phase 3 innovaTV 301 trial Genmab A/S (N…
Validation is supported by data from Phase 3 innovaTV 301 trial COPENHAGEN, Denmark, February 02, 2024 BUSINESS WIRE Genmab A/S …
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc.
Validation is supported by data from Phase 3 innovaTV 301 trial Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc.
- Genmab A/S(Nasdaq: GMAB) andPfizer, Inc.(NYSE PFE) today announced that the European Medicines Agency (EMA) has validated for…
COPENHAGEN, Denmark--(BUSINESS WIRE)-- Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc.
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc.
Abstract Background Bladder cancer is the second most common genitourinary malignancy worldwide.
Abstract Background Hepatocellular carcinoma (HCC) stands as a prevalent malignancy globally, characterized by significant…
2023年12月22日 アッヴィ合同会社 アッヴィ、治療歴のある非小細胞肺がん(NSCLC)患者さんを対象にテリソツズマブ ベドチンを評価した第II相LUMINOSITY試験について、良好なトップライン結果を発表 ー LUMINOSITY試験の各主要評価項目…
2023年12月22日 アッヴィ合同会社 アッヴィ、治療歴のある非小細胞肺がん(NSCLC)患者さんを対象にテリソツズマブ ベドチンを評価した第II相LUMINOSITY試験について、良好なトップライン結果を発表 ー LUMINOSITY試験の各主要評価項目…
配信元:共同通信PRワイヤー 2023年12月22日 アッヴィ合同会社 アッヴィ、治療歴のある非小細胞肺がん(NSCLC)患者さんを対象にテリソツズマブ ベドチンを評価した第II相LUMINOSITY試験について、良好なトップライン結果を発表 ー…
2023年12月22日 アッヴィ合同会社 アッヴィ、治療歴のある非小細胞肺がん(NSCLC)患者さんを対象にテリソツズマブ ベドチンを評価した第II相LUMINOSITY試験について、良好なトップライン結果を発表 ー LUMINOSITY試験の各主要評価項目…
2023年12月22日 アッヴィ合同会社 アッヴィ、治療歴のある非小細胞肺がん(NSCLC)患者さんを対象にテリソツズマブ ベドチンを評価した第II相LUMINOSITY試験について、良好なトップライン結果を発表 ー LUMINOSITY試験の各主要評価項目…
2023年12月22日 アッヴィ合同会社 アッヴィ、治療歴のある非小細胞肺がん(NSCLC)患者さんを対象にテリソツズマブ ベドチンを評価した第II相LUMINOSITY試験について、良好なトップライン結果を発表 ー LUMINOSITY試験の各主要評価項目…
2023年12月22日 アッヴィ合同会社 アッヴィ、治療歴のある非小細胞肺がん(NSCLC)患者さんを対象にテリソツズマブ ベドチンを評価した第II相LUMINOSITY試験について、良好なトップライン結果を発表 ー LUMINOSITY試験の各主要評価項目…
2023年12月22日 午前11時00分 2023年12月22日 アッヴィ合同会社 アッヴィ、治療歴のある非小細胞肺がん(NSCLC)患者さんを対象にテリソツズマブ ベドチンを評価した第II相LUMINOSITY試験について、良好なトップライン結果を発表 ー…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
PR Newswire NORTH CHICAGO, Ill., Nov. 29, 2023 LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
News provided by AbbVie Nov 29, 2023, 8:45 AM ET LUMINOSITY trial demonstrated compelling clinical benefits across key…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
KGET 17 Please enter a search term. Please enter a search term. News provided by Nov 29, 2023, 8:45 AM ET NORTH CHICAGO, Ill.…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
Published: Nov. 29, 2023 at 7:45 AM CST|Updated: 6 minutes ago LUMINOSITY trial demonstrated compelling clinical benefits…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
NORTH CHICAGO, Ill. In addition, other endpoints demonstrated meaningful clinical outcomes including median duration of…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
News provided by AbbVie 29 Nov, 2023, 08:45 ET LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints…
Published: Nov. 29, 2023 at 7:45 AM CST|Updated: moments ago LUMINOSITY trial demonstrated compelling clinical benefits across…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints Teliso-V is an investigational first-in-class, c…
Abstract The m6a demethyltransferase ALKBH5 dynamically modulates gene expression and intracellular metabolic molecules by…
Abstract Background The incidence and prevalence of nonalcoholic fatty liver disease related hepatocellular carcinoma (NAFLD-HCC…
Abstract Background Primary hepatocellular carcinoma (HCC) is a malignancy with high morbidity and mortality.
Abstract Background Drug resistance is a major obstacle causing chemotherapy failure, and enabling cancer progression.
Abstract Ovarian cancer (OV) is the most lethal gynecological malignancies worldwide.
Foto mostra menino doente em casa. Crédito: *Elisabete Weiderpass / The Conversation As terapias avançadas, inclusive aquelas…
Abstract Objective Herein, we aimed at exploring the FAP expression in clear cell renal cell carcinoma (ccRCC) along with its…
The resistance to cancer treatment is often credited to the heterogenous cellular nature within a tumor.
Abstract Background The long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) has been reported…
Jason Henry, MD As the second most common cause of cancer-related deaths globally, colon cancer is amongst the deadliest.1 An…
Abstract Background The B7-H3 protein, encoded by the CD276 gene, is a member of the B7 family of proteins and a transmembrane…
Benjamin Garmezy, MD Kidney and renal pelvis cancers are one of the 10 most common new malignant diagnoses in both men and…
This year alone, nearly 600,000 Americans will lose their lives to cancer. Recent estimates tell us that 41 percent of all…
LEIPZIG, Germany: Head and neck cancer is the sixth most common cancer worldwide and results in approximately 450,000 deaths…
Shuoshuo Sun Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine…